Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Sp...

por Hidalgo-Vega, Álvaro, Villoro, Renata, Blasco, Juan Antonio, Talavera, Pablo, Ferro, Belén, Purcaru, Oana
Publicado 2015

Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Resul...

por Sarzi-Puttini, Piercarlo, Filippucci, Emilio, Adami, Silvano, Meroni, Pier Luigi, Batticciotto, Alberto, Idolazzi, Luca, De Lucia, Orazio, Talavera, Pablo, Kumke, Thomas, Grassi, Walter
Publicado 2018